• SPX
  • $5,631.12
  • -0.04 %
  • -$1.97
  • DJI
  • $41,547.77
  • -0.18 %
  • -$74.32
  • N225
  • $36,203.22
  • -1.03 %
  • -$378.54
  • FTSE
  • $8,309.86
  • 0.38 %
  • $31.42
  • IXIC
  • $17,575.40
  • -0.1 %
  • -$16.73
Arvinas, Inc. (ARVN) Stock Price, News & Analysis

Arvinas, Inc. (ARVN) Stock Price, News & Analysis

Currency in USD Disclaimer

$25.53

$0.38

(1.49%)

Day's range
$25.06
Day's range
$25.97
50-day range
$23.1
Day's range
$34.11
  • Country: US
  • ISIN: US04335A1051
52 wk range
$13.57
Day's range
$53.08
  • CEO: Dr. John G. Houston Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.08
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (ARVN)
  • Company Arvinas, Inc.
  • Price $25.53
  • Changes Percentage (1.49%)
  • Change $0.38
  • Day Low $25.06
  • Day High $25.97
  • Year High $53.08

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $72.00
  • High Stock Price Target $123.00
  • Low Stock Price Target $24.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$6.05
  • Trailing P/E Ratio -4.41
  • Forward P/E Ratio -4.41
  • P/E Growth -4.41
  • Net Income $-367,300,000

Income Statement

Quarterly

Annual

Latest News of ARVN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.